Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOW-QUEL vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Low-Quel is a combination product containing an opioid agonist and a non-opioid analgesic. The opioid component acts on mu-opioid receptors in the central nervous system to alter pain perception, while the non-opioid component inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and providing additive analgesia.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate,Chronic pain management in opioid-tolerant patients
Prevention of pregnancy
10 mg orally twice daily; not to exceed 20 mg/day.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life is 12-15 hours in healthy adults; increases to 20-24 hours in hepatic impairment and 18-22 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
The opioid component is primarily metabolized by CYP3A4 and CYP2D6, with conjugation as a minor pathway. The non-opioid analgesic is extensively metabolized in the liver via glucuronidation and sulfation, with minor contributions from CYP450 enzymes.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal excretion of unchanged drug accounts for 60-70% of elimination; hepatic metabolism accounts for 20-30% (primarily CYP3A4); biliary/fecal excretion of metabolites accounts for <10%.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
94-97% bound to albumin; minor binding to alpha-1-acid glycoprotein.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Vd is 4-6 L/kg, indicating extensive tissue distribution (e.g., lung, liver, kidney, brain).
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral bioavailability is 70-80% (first-pass metabolism reduces from 95% absorption); bioavailability is reduced by 20-30% with high-fat meal.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
GFR 30-59 m L/min: 10 mg once daily; GFR 15-29 m L/min: 5 mg once daily; GFR <15 m L/min: not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
0.2 mg/kg orally twice daily; maximum 10 mg/day.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Initial 5 mg orally once daily; titrate cautiously to 10 mg/day.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from the non-opioid component.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Life-threatening respiratory depression; addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; risks from concomitant use with CNS depressants; severe hypotension; adrenal insufficiency; hepatotoxicity; gastrointestinal bleeding; renal impairment; seizures; and serotonin syndrome.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; hypersensitivity to any component; and concurrent use of MAO inhibitors or within 14 days of such therapy.
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid grapefruit and grapefruit juice as they may increase quetiapine levels. Take with a light meal to reduce GI upset. Avoid high-fat meals when taking extended-release formulations.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
No adequate human studies; animal studies not available. First trimester risk unknown; second and third trimester: potential for fetal hyperinsulinemia and hypoglycemia if used near term.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Excretion in human milk unknown; M/P ratio not determined. Use caution due to potential for adverse effects in nursing infant.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No standard dose adjustment required; consider increased monitoring for hypoglycemia due to altered pharmacokinetics in pregnancy.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
LOW-QUEL is a low-dose quetiapine formulation (e.g., 25-50 mg) used off-label for insomnia. Monitor for somnolence, orthostatic hypotension, and weight gain. Avoid in patients with QTc prolongation or uncontrolled diabetes. Taper slowly after long-term use to avoid rebound insomnia.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take exactly as prescribed, usually 1-2 hours before bedtime.,Do not drive or operate machinery until you know how this drug affects you.,Avoid alcohol and other sedatives while taking this medication.,Report any fainting, fast heartbeat, or unusual movements to your doctor.,Do not stop suddenly; dosages must be tapered gradually.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOW-QUEL vs ALYACEN 1/35, answered by our medical review team.
LOW-QUEL is a Oral Contraceptive that works by Low-Quel is a combination product containing an opioid agonist and a non-opioid analgesic. The opioid component acts on mu-opioid receptors in the central nervous system to alter pain perception, while the non-opioid component inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and providing additive analgesia.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOW-QUEL and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOW-QUEL is: 10 mg orally twice daily; not to exceed 20 mg/day.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOW-QUEL and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOW-QUEL is classified as Category C. No adequate human studies; animal studies not available. First trimester risk unknown; second and third trimester: potential for fetal hyperinsulinemia and hypoglycemia if used nea. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.